Mundipharma and Cidara Therapeutics, Inc.: Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Invasive Candidiasis

For Trade and Medical Media Only Rezafungin is a next-generation once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis

Related Keywords

California ,United States ,San Diego ,Japan ,Canada ,United Kingdom ,America ,Taylor Sandison ,Patrick Bursey ,Brian Sheehan ,Jan Milton Edwards ,Asia Pacific ,Brian Ritchie ,Community Register ,Cidara Therapeutics Inc ,European Commission ,Drug Administration ,Nasdaq ,Exchange Commission ,Us Food Drug Administration ,Lifesci Communications ,European Medicines Agency ,Securities Exchange ,Healthcare Products Regulatory Agency ,For Trade ,Medical Media Only ,Innovation Medicine ,Early Access ,Medicines Scheme ,Cidara Therapeutics ,Promising Innovative Medicine ,Chief Scientific Officer ,Chief Medical Officer ,New Drug Application ,Marketing Authorization Application ,Qualified Infectious Disease Product ,Fast Track ,Orphan Drug Designation ,Latin America ,Pain Management ,Infectious Disease ,Consumer Healthcare ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Quarterly Report ,Mundipharma Announce Positive Topline Results ,Global Phase ,Search Orphan Drug Designations ,Sci Advisors ,Sci Communications ,Mundipharma ,Bidara ,Herapeutics ,Ezafungin ,Warded ,Romising ,Innovation ,Medicine ,Resignation ,Medicines ,Healthcare ,Products ,Egulatory ,Agency ,Phra ,Treatment ,Nvasive ,Candidiasis ,